About SOFIE

This company develops molecular imaging probes and devices for in-vivo research, enabling the visualization of tumors that respond to specific drugs. Their technology assists in personalized healthcare by providing tools for patient-specific treatment selection.

```xml <problem> Visualizing tumors and their response to specific drugs in vivo can be challenging, hindering the development of personalized healthcare strategies. Current methods may lack the sensitivity and specificity needed for effective patient-specific treatment selection. </problem> <solution> SOFIE Biosciences develops and delivers molecular diagnostics and therapeutics, focusing on radiopharmaceuticals for PET imaging. They offer a range of imaging tracers, including Flurpiridaz F 18, Pylarify, and Neuraceq, along with contract manufacturing services for diagnostic and therapeutic compounds. SOFIE's FAPI compounds, labeled with Gallium-68 and Fluorine-18, enable non-invasive visualization of fibroblast activation protein (FAP) for oncology and non-oncology indications. Their radiopharmaceutical contract manufacturing (RCM) services support diagnostic and therapeutic compounds from R&D through clinical trials and commercial manufacturing, adhering to strict CGMP standards. </solution> <features> - Development of FAPI-46 (Ga-68) and FAPI-74 (F-18) PET tracers for imaging of fibroblast activation protein - Contract manufacturing services for radiopharmaceuticals, adhering to 21 CFR 211 and 212 CGMP standards - Network of radiopharmacies providing reliable delivery of high-quality radiopharmaceuticals - Manufacturing capabilities include ISO 5 to 7 clean room classifications and high-volume dispensing - Global distribution network with temperature monitoring to ensure product integrity - Clinical development of FAPI compounds with demonstrated favorable biodistribution and target-specific uptake </features> <target_audience> SOFIE serves pharmaceutical companies, distribution networks, and medical professionals seeking advanced molecular diagnostics and therapeutics, as well as clinical trial support and radiopharmaceutical manufacturing services. </target_audience> ```

What does SOFIE do?

Where is SOFIE located?

SOFIE is based in United States.

When was SOFIE founded?

SOFIE was founded in 2008.

Location

United States

Founded

2008

Employees

331 employees

Major Investors

Trilantic North America

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

SOFIE

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

sofie.com 7K+

Crunchbase

Founded 2008 – United States

Funding

Major Investors

Trilantic North America

Team (250+)

No team information available.

Company Description

Problem

Visualizing tumors and their response to specific drugs in vivo can be challenging, hindering the development of personalized healthcare strategies. Current methods may lack the sensitivity and specificity needed for effective patient-specific treatment selection.

Solution

SOFIE Biosciences develops and delivers molecular diagnostics and therapeutics, focusing on radiopharmaceuticals for PET imaging. They offer a range of imaging tracers, including Flurpiridaz F 18, Pylarify, and Neuraceq, along with contract manufacturing services for diagnostic and therapeutic compounds. SOFIE's FAPI compounds, labeled with Gallium-68 and Fluorine-18, enable non-invasive visualization of fibroblast activation protein (FAP) for oncology and non-oncology indications. Their radiopharmaceutical contract manufacturing (RCM) services support diagnostic and therapeutic compounds from R&D through clinical trials and commercial manufacturing, adhering to strict CGMP standards.

Features

Development of FAPI-46 (Ga-68) and FAPI-74 (F-18) PET tracers for imaging of fibroblast activation protein

Contract manufacturing services for radiopharmaceuticals, adhering to 21 CFR 211 and 212 CGMP standards

Network of radiopharmacies providing reliable delivery of high-quality radiopharmaceuticals

Manufacturing capabilities include ISO 5 to 7 clean room classifications and high-volume dispensing

Global distribution network with temperature monitoring to ensure product integrity

Clinical development of FAPI compounds with demonstrated favorable biodistribution and target-specific uptake

Target Audience

SOFIE serves pharmaceutical companies, distribution networks, and medical professionals seeking advanced molecular diagnostics and therapeutics, as well as clinical trial support and radiopharmaceutical manufacturing services.